13F Holdings
中文EN

CYTK CYTOKINETICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1061983 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY29.9%
TTM net income YoY-3.5%
TTM EPS YoY4.4%
Revenue 3-yr CAGR143.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-625.2%
Net margin-686.6%
FCF margin-519.5%
EBITDA margin-613.2%

Returns

ROE—
ROA-47.7%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets117.6%
Debt / equity—
Current ratio3.36x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue14.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$88.04M$18.47M$7.53M$94.59M$70.43M
R&D expense$416.03M$339.41M$330.12M$240.81M$159.94M
SG&A expense$284.27M$215.31M$173.61M$177.98M$96.80M
Operating income-$612.26M-$536.25M-$496.20M-$324.20M-$186.31M
Interest expense$45.58M$37.70M$28.31M$19.41M$16.44M
Income tax$0$0$0$0$0
Net income-$784.96M-$589.53M-$526.24M-$388.95M-$215.31M
EBITDA-$602.13M-$526.72M-$484.31M-$318.39M-$184.04M
EPS (basic)-6.54-5.26-5.45-4.33-2.80
EPS (diluted)-6.54-5.26-5.45-4.33-2.80
Weighted avg. shares (diluted)120,103111,97996,52489,82576,886
Balance sheet
Cash & equivalents$122.52M$94.86M$113.02M$65.58M$112.67M
Short-term investments$759.70M$981.16M$501.80M$717.00M$358.97M
Receivables$17.76M$16.65M$1.28M$147,000$51.82M
Inventory$0————
Current assets$916.98M$1.11B$628.05M$795.19M$535.67M
PP&E, net$79.19M$65.81M$68.75M$80.45M$73.27M
Total assets$1.42B$1.40B$824.32M$1.01B$841.32M
Current liabilities$202.45M$179.67M$102.68M$84.62M$71.86M
Short-term debt$41.18M$11.52M$10.08M$958,000—
Long-term debt$246.38M$93.23M$58.38M$63.81M$47.37M
Total debt$287.56M$104.75M$68.46M$64.77M$47.37M
Total liabilities$2.08B$1.54B$1.21B$1.12B$597.46M
Shareholders' equity-$659.62M-$135.37M-$386.32M-$107.90M$243.86M
Net debt$165.05M$9.89M-$44.56M-$814,000-$65.30M
Shares outstanding122.94M118.21M101.64M94.83M84.80M
Cash flow statement
Operating cash flow-$510.01M-$395.89M-$414.33M-$299.52M-$142.52M
Capital expenditure$24.81M$3.91M$1.42M$11.34M$48.87M
Free cash flow-$534.82M-$399.80M-$415.75M-$310.85M-$191.39M
Investing cash flow$16.67M-$553.10M$239.25M-$262.13M-$147.78M
Financing cash flow$524.46M$930.61M$221.32M$516.17M$319.98M
Depreciation & amortization$10.12M$9.53M$11.89M$5.81M$2.28M
Stock-based compensation$112.29M$97.84M$72.06M$47.85M$26.83M

Free plan shows the latest 5 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.